Drug intelligence / Profile preview

INV-003

Development stage: Preclinical
Lead developer: Innovac Therapeutics
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules
Administration: Not Specified (likely Intravenous Or Intramuscular Depending On The Formulation And Indication)

Overview

INV-003 refers to at least two distinct investigational drugs in preclinical development by different companies. One version, developed by Inventera, is a diagnostic radiopharmaceutical intended as a contrast agent for imaging applications. The other, developed by Innovac Therapeutics USA, Inc., is an mRNA-based therapeutic vaccine targeting neoplasms (cancers), with additional exploration for infectious diseases. Both are in preclinical stages and have not yet entered clinical trials or received regulatory approval[1][3].

Beyond the preview

Go deeper on INV-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-003.

Explore the full profile